Japan could become one of the first countries in the world to end the HIV epidemic, says the president of Gilead Sciences Japan, Kennet Brysting. The idea for now could seem a little too ambitious, but it is not entirely unrealistic, given that the availability of medicines that can prevent transmission of HIV. Drugs are not the cure, but control over the spread of virus to the point where the disease is no longer a major public health threat.

What Is The Role Of Preventative HIV Medicines?

Gilead's have two key drugs, Truvada and lenacapavir. These two are playing a crucial role in prevention. Truvada is taken as a daily pill, while lenacapavir requires two injections per year. It can make the virus undetectable in infected individuals and prevent transmission to those who are not infected yet. In trials, lenacapavir showed 100% efficacy in preventing HIV infections. This is why it is describe as "almost a vaccine".

In 2024, Japan also approved Truvada for HIV prevention, but the country has yet to approve lenacapavir for the same. Until now, people in Japan had been importing generic versions of Truvada or purchasing it from clinics that source it from overseas.

HIV In Japan

Up until now, Japan reported around 25,000 HIV infections, whereas 669 new cases were reported in 2023. For seven consecutive years, the number of new infections remained under 1,000. The downward trend thus shows that the virus has been controlled, however, getting to zero new infections remains the ultimate goal.

Brysting too acknowledged that simply having effective drug is not enough. What is important is to have a proper implementation, access and healthcare support to make sure that these treatments are widely available and effective.

What Are The Challenges In Implementation?

The biggest challenges is testing rates. There is a need to increase testing rates. At this very moment, around 86% people infective with Japan have been tested, but the goal is to increase it up to 95%, with an ideal goal of 100%. Without widespread testing, many infected people may not even know that they are infected and it could transmit the virus.

Another measure issue is the cost of preventative medication. While Japan's health insurance covers treatments for diseases, it does not cover preventative drugs. Those who purchase Truvada for prevention, pay around $470 per month. Some clinics in Tokyo offer generic alternatives too, which is cheaper, but they are not ideal.

Better Healthcare Support

Brysting expressed concern that individuals importing medications might not be consulting doctors regularly, which is essential for monitoring HIV status and overall health. Truvada users need to be tested for HIV initially and every three months, along with screenings for other infections and kidney function checks. Without proper medical supervision, there is a risk of misuse and inadequate protection.

Gilead is in discussions with Japanese authorities to improve access and insurance coverage for Truvada, and progress is being made. Japan has shown efficiency in approving critical medicines, as seen during the COVID-19 pandemic when Gilead’s remdesivir was approved in just three days.

What Is The Way Ahead?

Gilead at this moment is not only focused on HIV and hepatitis C, but also expanding into oncology with innovative treatments like CAR-T cell therapy, which strengthens a patient's immune system to fight cancer.

However, Japan’s strict approval processes can slow down drug availability. Phase 3 clinical trials often need to be conducted within the country, and Japan tends to approve medicines much later than other regions. For instance, Truvada was approved for prevention in Japan 12 years after the U.S. and nearly 20 years after its approval for treatment. inancial factors also play a role. The Japanese government adjusts drug prices annually, often reducing them, which can make long-term investment challenging for pharmaceutical companies.

The Donald Trump administration plans to end Medicare Part D premium subsidies after 2026, ending a program that has helped keep prescription drug plan premiums stable, according to the Centers for Medicare & Medicaid Services (CMS).

The decision could affect millions of Americans, particularly those aged 65 and older, who may face higher prescription drug costs beginning next year.

The CMS said its review of insurers' 2027 bids found that health plans now have sufficient experience to accurately price Medicare Part D plans without government support, according to The Wall Street Journal.

Subsidy Program to End After 2026

The program, to end after 2026, provides insurance companies with an estimated $3.6 billion in subsidies this year to limit premium increases for Part D plans.

"We are stabilizing the market so this bailout is no longer needed. Premiums will go up by less than $10 for most ⁠Medicare recipients, with many even seeing lower premiums," CMS Administrator Dr. Mehmet Oz said in a post on X.

"Every Medicare beneficiary still has access to low-cost plans, and we will continue to lower prescription drug prices for every American patient, from more MFN deals to our policy giving seniors access to GLP-1s for $50 a month,” he added.

Who Could Be Affected?

Around 25 million Americans enrolled in traditional Medicare have stand-alone Part D prescription drug plans, paying an average monthly premium of $36, according to KFF.

Another 31 million beneficiaries receive prescription drug coverage through Medicare Advantage, the privately managed alternative for people aged 65 and older.

The previous Biden administration had introduced the subsidy program ahead of the 2024 presidential election to offset policy changes that would have sharply increased Medicare Part D premiums in 2025.

Dr Oz said that the Biden administration’s approach was “unacceptable” and that it “gave BILLIONS of taxpayer money DIRECTLY to Big Insurance Companies.”

Uncertainty Over Premium Increases

However, it remains unclear how many beneficiaries will pay more or how large those increases will be. Premiums vary by plan, and beneficiaries will have an opportunity to compare and switch coverage during this fall's enrollment period. CMS said premiums for individual plans will be released in September.

AHIP, a major trade group representing health insurers, said it is reviewing the announcement, the New York Times reported.

“At a time of sharply rising prescription drug costs, health plans are focused on keeping Part D coverage and benefits as affordable as possible,” said Chris Bond, a spokesman, in a statement.

A Trump administration official told Bloomberg that the majority of older Americans will see no increase in premiums or may even pay less.

CMS Releases Preliminary 2027 Part D Details

CMS also released preliminary information on 2027 Medicare drug plan bids. The national average monthly bid amount, used to calculate government subsidies for plans, will be $296.05 in 2027.

The agency said the national base beneficiary premium for Medicare Part D will be $41.33 next year. Annual increases will remain capped at 6% through 2029 under provisions of the Inflation Reduction Act.

More than six years after the COVID-19 pandemic devastated the world, newly released personal journals of former National Institute of Allergy and Infectious Diseases (NIAID) Director Dr. Anthony Fauci are giving a raw glimpse into the behind-the-scenes discussions, scientific uncertainty, and political tensions that clouded United States' pandemic response.

The 1,141-page collection, released by Senator Rand Paul ahead of Fauci's scheduled Senate testimony, chronicles events from December 2019 through December 2022.

Announcing the release of Fauci's journals, Sen. Rand Paul said, "The American people deserve the truth about what happened during the COVID-19 pandemic. Dr. Fauci's own contemporaneous writings provide an unprecedented window into the decisions, discussions, and uncertainties that shaped the federal response."

The journals have reignited debate over the origins of SARS-CoV-2 and Fauci's role during one of the most challenging public health crises of recent times.

However, experts say that the diaries represent Fauci's personal contemporaneous notes and do not conclusively establish the origin of COVID-19.

Major COVID-related Revelations From Dr Anthony Fauci's Diary

Uncertainty About COVID-19's Origin

One of the biggest revelations is that Anthony Fauci recorded discussions in late January 2020 in which several scientists raised questions about whether SARS-CoV-2 could have originated from a laboratory because of certain genetic features.

The diary shows these possibilities were discussed internally before scientists later concluded that natural spillover was the more likely. The diary does not provide proof that the virus leaked from a lab.

Fauci wrote, "The first infection was in early December and was not connected to the market... Now we know the market was not the source, it was the amplifier. Having said that, somewhere the virus jumped from animals to humans."

Also read: Trump Should Take A Month Off For His Health, Says Bill O'Reilly

The Lab Leak

The entries reveal Fauci continued receiving updates about the virus's origin while publicly emphasizing the available scientific evidence supporting natural emergence.

After a conference call with leading virologists, Fauci wrote that several experts discussed whether part of the virus genome could have evolved naturally. He listed the participants and summarized the debate over the possibility of a laboratory origin.

COVID-19 Initially Viewed As Severe Influenza

Early diary entries describe the outbreak as looking similar to "bad influenza" before severe complications became clear. This reflects the limited knowledge available in January and early February 2020.

School Closures

Fauci's notes reportedly show he was conflicted about balancing infection control against the educational and mental health consequences of prolonged school closures, highlighting the uncertainty policymakers faced.

Also read: Ebola Outbreak in DR Congo Nears 3,000 Cases, 1,300 Deaths as UN Warns Virus Is 'Spreading Like Wildfire'

Internal Frustration

The diary documents Fauci's concerns about bureaucratic delays, operational problems, and disagreements within the federal government during the early COVID-19 response, suggesting these challenges complicated public health decision-making.

Overshadowing President Donald Trump

The entries describe Fauci's dynamic with President Donald Trump, disagreements over masks, hydroxychloroquine, and public messaging, and concerns about how politics affected science.

He wrote, "AMAZING interaction with POTUS... It was a disturbingly rambling discussion since he kept talking about TV ratings, and HC (Hydroxychloroquine), and influenza and virtually everything else as I was trying to keep him on track."

He also wrote about outshining President Trump. "Apparently the WH is very upset that I am being profiled and it looks like I am putting down the POTUS and becoming a star that outshines him. ... Very stressful!!"

He also wrote that Trump praised him. "As usual, POTUS was very warm and friendly with me... 'I love you, Tony. I feel like giving you a big hug.'"

Media Attention

The journals reveal Fauci's obsession with his fame due to widespread media coverage and his efforts to maintain public trust. He wrote, "For better or worse, I am becoming an international celebrity. Calls from all over the world."

He added, "WH press conference picked up by many outlets. Many print profiles and features on me. Ridiculous, too numerous to count! ... Press is going wild with me."

Fauci's diary sparked a lot of responses from politicians and health experts.

He said, "He lied about masks. He lied about social distancing. He lied about transmission. He lied about natural immunity. He lied about the vaccine's capacity to prevent infection."

He added. "Dr. Fauci did incalculable damage to public health and to the public's trust in government. "He prioritized getting on TV over protecting public health."

Olympic hurdler and bobsledder Lolo Jones has revealed that she suffered a debilitating spinal injury during bobsled training, lost bladder control, and was allegedly denied timely medical care, raising serious concerns about athlete health and safety within the U.S. Olympic system.

Jones shared her experience after reports of the the events surrounding a training accident ahead of the 2025 IBSF World Championships in Lake Placid surfaced.

According to the reports, she sustained a severe lower back injury while testing a new bobsled but continued competing because her condition was never diagnosed at the time.

What Happened?

During the training session, Lolo Jones experienced symptoms like intense lower back pain, numbness, leg weakness, foot drop, and loss of bladder control; all of which can be warning signs of cauda equina syndrome, a rare but serious condition caused by compression of nerves at the base of the spinal cord.

It is a medical emergency as delayed treatment can result in permanent paralysis or loss of bladder and bowel function.

Despite these symptoms, Jones alleges she did not receive urgent medical evaluation. Reports claim that when she visited the U.S. Olympic Training Center's sports medicine clinic seeking treatment, her scheduled massage appointment had been canceled, and she was not provided immediate imaging such as an MRI or X-ray.

Convinced she was dealing with a painful but manageable injury, Jones continued to compete in the World Championships, completing multiple high-speed bobsled runs. She later said that had the sled crashed during competition, she could have been left permanently paralysed.

After returning home, Jones reportedly paid for her own MRI, which revealed the extent of the damage. The scan showed a herniated disc, additional disc bulges, and tears involving the L3, L4 and L5 levels of her spine, with leaking spinal fluid. She subsequently underwent spinal surgery at her own expense.

Jones also claims that after surgery she was denied access to training and rehabilitation facilities at the Olympic Training Center, forcing her to fund her own recovery, rehabilitation, travel and training. According to reports, the financial burden exceeded $100,000.

The athlete has since called for greater accountability and reforms in athlete medical care, especially who compete in the Olympics.

In a public statement, Jones wrote that she had "never even been given an X-ray or an MRI" despite her symptoms and said she wanted to help ensure other athletes do not face similar situations.

Also read: Teenage Powerlifting Champion Dies At 17, After 600lb Barbell Falls On Neck- What Went Wrong And How Could It Have Been Prevented?

Early Detection Is Essential

Experts consider loss of bladder control, leg weakness, numbness around the saddle area, and severe lower back pain to be serious symptoms that need immediate emergency assessment.

Prompt diagnosis, usually with an MRI, and urgent surgery when cauda equina syndrome is confirmed can significantly improve the chances of preserving nerve function and preventing the risk of paralysis.

Jones is one of the few athletes to have competed at both the Summer and Winter Olympics, representing the United States in hurdles and bobsled.

Her latest allegations have sparked renewed discussion about whether elite athletes receive timely access to appropriate medical attention when serious injuries occur.